Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis
- PMID: 34367495
- PMCID: PMC8326161
- DOI: 10.4254/wjh.v13.i7.731
Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis
Abstract
Portal hypertension (PH), a common complication of liver cirrhosis, results in development of esophageal varices. When esophageal varices rupture, they cause significant upper gastrointestinal bleeding with mortality rates up to 20% despite state-of-the-art treatment. Thus, prophylactic measures are of utmost importance to improve outcomes of patients with PH. Several high-quality studies have demonstrated that non-selective beta blockers (NSBBs) or endoscopic band ligation (EBL) are effective for primary prophylaxis of variceal bleeding. In secondary prophylaxis, a combination of NSBB + EBL should be routinely used. Once esophageal varices develop and variceal bleeding occurs, standardized treatment algorithms should be followed to minimize bleeding-associated mortality. Special attention should be paid to avoidance of overtransfusion, early initiation of vasoconstrictive therapy, prophylactic antibiotics and early endoscopic therapy. Pre-emptive transjugular intrahepatic portosystemic shunt should be used in all Child C10-C13 patients experiencing variceal bleeding, and potentially in Child B patients with active bleeding at endoscopy. The use of carvedilol, safety of NSBBs in advanced cirrhosis (i.e. with refractory ascites) and assessment of hepatic venous pressure gradient response to NSBB is discussed. In the present review, we give an overview on the rationale behind the latest guidelines and summarize key papers that have led to significant advances in the field.
Keywords: Endoscopy; Non-selective betablockers; Portal hypertension; Transjugular intrahepatic portosystemic shunt.
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: Pfisterer N and Unger LW declare no conflicts of interest related to this manuscript. Reiberger T received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Abbvie, Boehringer-Ingelheim, Gilead and Roche.
Figures


Similar articles
-
Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.Endoscopy. 2022 Nov;54(11):1094-1120. doi: 10.1055/a-1939-4887. Epub 2022 Sep 29. Endoscopy. 2022. PMID: 36174643
-
Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding.Aliment Pharmacol Ther. 2018 Apr;47(7):966-979. doi: 10.1111/apt.14485. Epub 2018 Feb 1. Aliment Pharmacol Ther. 2018. PMID: 29388229
-
Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.Liver Int. 2023 Jun;43(6):1183-1194. doi: 10.1111/liv.15559. Epub 2023 Apr 17. Liver Int. 2023. PMID: 36897563 Review.
-
Treatment of Oesophageal Varices in Liver Cirrhosis.Digestion. 2019;99(4):261-266. doi: 10.1159/000492076. Epub 2018 Sep 13. Digestion. 2019. PMID: 30212817
-
Prevention and treatment of variceal haemorrhage in 2017.Liver Int. 2017 Jan;37 Suppl 1:104-115. doi: 10.1111/liv.13277. Liver Int. 2017. PMID: 28052623 Review.
Cited by
-
Statins, metformin, and RAS inhibitors did not reduce variceal bleeding risk and mortality in a large, real-life cohort of patients with cirrhosis.PLoS One. 2024 Jun 13;19(6):e0302811. doi: 10.1371/journal.pone.0302811. eCollection 2024. PLoS One. 2024. PMID: 38870117 Free PMC article.
-
The Prediction and Treatment of Bleeding Esophageal Varices in the Artificial Intelligence Era: A Review.Cureus. 2024 Mar 8;16(3):e55786. doi: 10.7759/cureus.55786. eCollection 2024 Mar. Cureus. 2024. PMID: 38586705 Free PMC article. Review.
-
Prospects for treatment of esophageal varices considering the safety of endoscopic band ligation.Hepatol Int. 2023 Oct;17(5):1079-1081. doi: 10.1007/s12072-023-10560-7. Epub 2023 Jul 8. Hepatol Int. 2023. PMID: 37421587 No abstract available.
-
Management of non-cirrhotic variceal bleeding in pregnant women with Budd-Chiari syndrome in the early second trimester: A case report.Narra J. 2024 Apr;4(1):e245. doi: 10.52225/narra.v4i1.245. Epub 2024 Jan 28. Narra J. 2024. PMID: 38798860 Free PMC article.
-
Efficacy and safety of transjugular intrahepatic portosystemic shunt versus endoscopic variceal ligation for variceal rebleeding: a systematic review and meta-analysis.Ann Med Surg (Lond). 2025 Apr 2;87(5):2936-2947. doi: 10.1097/MS9.0000000000003215. eCollection 2025 May. Ann Med Surg (Lond). 2025. PMID: 40337405 Free PMC article.
References
-
- Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: Concept to treatment. J Hepatol . 2015;62:S15–24. - PubMed
-
- García-Pagán JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol. 2012;57:458–461. - PubMed
-
- Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M, Zoller H, Schöfl R, Fickert P. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III) Wien Klin Wochenschr. 2017;129:135–158. - PMC - PubMed
-
- Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362:823–832. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources